

Live-Cell Microfluidic Platform – Unlocking Novel Biomarkers, Cell-Based Assays and Diagnostics

Cellanyx Diagnostics News – Announcement of New Board Member Dr. Catherine Fink

July 1, 2013

Cellanyx is pleased to announce the appointment of Dr. Catherine Fink to its Senior Advisory Board. Board members play a vital role in a company as they help better understand the market, assess financial conditions that will continue to strengthen the company, advise on clinical and technical developments, and share business and regulatory practices that keep the company operating according to the highest standards.

Dr. Fink comes with tremendous business and leadership talent. Dr. Fink is the founder of Medical Diagnostic Technology Evaluation. She has over 20 years of product development and operations experience in the in-vitro diagnostics industry. She is an experienced consultant providing technical, operations, regulatory compliance and business development expertise to her clients. Dr. Fink was formerly Vice President and General Manager at Corgenix, Inc., a company that develops and manufactures innovative products for hemostasis, autoimmune and vascular disease markets. After leaving Corgenix she continued to chair the Scientific Advisory Board. Prior to joining Corgenix, she was responsible for optical based biosensor technology development for bio-warfare detection with DDX, Inc. In Ireland, Dr. Fink was responsible for development of rapid saliva and blood based diagnostic tests for infectious diseases at Trinity Biotech. She began her career in industry with a startup company, BioSyn, Ltd., based at Queen's University in Belfast, developing peptide based diagnostics tests for cancer. Dr. Fink has published scientific articles and is named as inventor on several diagnostic related patents. Dr. Fink holds a Ph.D. in Immunology from The National University of Ireland and a B.Sc. degree in Zoology and Pharmacology from University College Dublin.

Dr. Fink is eager to gain a more in-depth understanding of the cancer diagnostics sector, tour Cellanyx's facilities and begin service to the Board. Cellanyx expects that she will bring strong insights and great value to the organization.

Cellanyx is combining advances in microfluidics, bioengineering, machine vision and cellomics to provide a state-of-the-art live-cell cancer diagnostic solution.

###

For more information, news, and perspectives from Cellanyx, please visit the website at <http://www.cellanyx.com>, or please contact:

Cellanyx Diagnostics, Inc.
One Marina Park Drive,
14th floor
Boston, MA, 02210
Main: 571.212.9991
Email: info@cellanyx.com